In-clinic Patient Conversations on Improving Obesity Care with Glucagon-Like Peptide-1 Receptor Agonist

Improving obesity care requires effective in-clinic communication that addresses stigma, builds readiness, and supports long-term adherence to evidence-based therapy. This review focuses on patient–clinician conversations around obesity management with semaglutide, emphasizing nonstigmatizing language, motivational interviewing, realistic expectation-setting, and early tolerability counseling. Data from Awareness, Care, and Treatment in Obesity MaNagement (ACTION) and ACTION-India highlight persistent gaps in obesity discussions, frequent negative patient emotions during weight-related consultations, and unrealistic weight-loss expectations among people with obesity. The manuscript integrates behavioral concepts, including internalized weight bias, expectations, and hedonic “wanting,” and applies these to practical obesity counseling. It further outlines a structured communication pathway across readiness assessment, staging, treatment selection, and continuity of care. Within this framework, semaglutide is positioned as a high-efficacy option whose successful initiation and persistence depend on linking treatment to meaningful health goals, proactively addressing gastrointestinal adverse effects, and setting realistic timelines for response. Overall, the review supports a communication-centered, patient-aligned approach to obesity care in which trust-building, shared decision-making, and structured follow-up are essential to optimize adherence and long-term outcomes with semaglutide.